Assessing the translatability of drug projects: What needs to be scored to predict success?

Nature Reviews Drug Discovery

Volumn 8, Issue 7, 2009, Pages 541-546

  Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BACLOFEN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; IPRATROPIUM BROMIDE; POTASSIUM CHANNEL HERG; TIOTROPIUM BROMIDE;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL STUDY; GENE EXPRESSION; HUMAN; LICENSING; NONHUMAN; PATENT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; SCORING SYSTEM; TOXICITY TESTING; VALIDITY;

BIOLOGICAL MARKERS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 67650069258     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2898     Document Type: Article

References (27)

1. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
2. Nishimura, T. et al. Disease proteomics toward bedside reality. J. Gastroenterol. 40 S7-S13 (2005).
3. Wehling, M. Translational medicine: Science or wishful thinking? J. Transl. Med. 6, 31-33 (2008).
4. Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Products. FDA website [online], http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ ucm113411.pdf (2004).
5. National Institutes of Health, Department of Health and Human Services. Clinical and Translational Science Awards. NIH website [online], http://www.ncrr.nih.gov/clinical_research_resources/ clinical_and_translational_science_awards/ (2006).
6. The European Advanced Translational Research Infrastructure in Medicine. Medical translation of basic research discoveries into clinical applications - a major challenge. EATRIS website [online], http://www.eatris.eu/ (2008).
7. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758 (1999).
8. Food and Drug Administration. Critical Path Opportunities Report. FDA website [online], http://www.fda.gov/downloads/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ UCM077254.pdf (2006).
9. Burckart, G. J. et al. Qualification of biomarkers for drug development in organ transplantation. Am. J. Transplant. 8, 267-270 (2008).
10. European Medicines Agency. Medicines and Emerging Science. EMEA website [online], http://www.emea.europa.eu/htms/human/mes/ biomarkers.htm (2008).
11. The Biomarkers Consortium. Beta Cell Function Symposium. The Biomarkers Consortium website [online], http://www.biomarkersconsortium.org/index.php?option= com_content&task=category§ionid=8&id=30&Itemid=61 (2009).
12. National Cancer Institute. Early Detection Reserach Network. NCI website [online], http://edrn.nci.nih.gov/about-edrn/ scicomponents (2009).
13. Love, D. R. et al. Modeling inflammatory bowel disease: The zebrafish as a way forward. Expert Rev. Mol. Diagn. 7, 177-193 (2007).
14. Helgadottir, A. et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nature Genet. 38, 68-74 (2006).
15. Jones, R., Armstrong, D., Malfertheiner, P. & Ducrotte, P. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Curr. Med. Res. Opin. 22, 657-662 (2006).
16. Coron, E., Hatlebakk, J. G. & Galmiche, J. P. Medical therapy of gastroesophageal reflux disease. Curr. Opin. Gastroenterol. 23 434-439 (2007).
17. B agonist baclofen in patients with symptoms and duodenogastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52, 1397-1402 (2003).
18. Voshaar, T. et al. A randomized study of tiotropium Respimat Soft MistInhaler vs. ipratropium pMDI in COPD. Respir. Med. 102, 32-41 (2008).
19. Curry, S. H. Translational science: Past, present, and future. Biotechniques 44, ii-viii (2008).
20. Wehling, M. Translational medicine: Can it really facilitate the transition of research "from bench to bedside"? Eur. J. Clin. Pharmacol. 62, 91-95 (2006).
21. Wehling, M. Translational science in medicine - implications for the pharmaceutical industry. Int. J. Pharm. Med. 20, 303-310 (2006).
22. Schmidt, B. Proof of principle studies. Epilepsy Res. 68, 48-52 (2006).
23. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44, 235-249 (2000).
24. Izzo, J. L. Jr. Stagnation and the critical need for hypertension subtyping. J. Clin. Hypertens. (Greenwich). 10, 174-175 (2008).
25. Woo, S. & Jusko, W. J. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab. Dispos. 35, 1672-1678 (2007).
26. Kummar, S. et al. Phase 0 clinical trials: Conceptions and misconceptions. Cancer J. 14, 133-137 (2008).
27. Mitcheson, J. S. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem. Res. Toxicol. 21, 1005-1010 (2008).